涉嫌单位行贿罪被移送起诉，信邦制药多项业务毛利率下滑

Core Viewpoint - Xinbang Pharmaceutical has been prosecuted for alleged unit bribery, leading to a significant drop in its stock price, despite efforts to control costs and ongoing challenges in its business performance [2][12][19] Group 1: Legal Issues - On December 10, Xinbang Pharmaceutical announced that it was sent for prosecution by the supervisory committee due to alleged unit bribery, potentially related to its acquisition of Guizhou Kekai Pharmaceutical [2][3] - The case involves former chairman An Huailuo and has been linked to corruption details surrounding the acquisition of Kekai Pharmaceutical [5][15] - The company received legal notifications regarding the prosecution, indicating that the case is currently in the review stage [13][14] Group 2: Stock Market Reaction - Following the announcement, Xinbang Pharmaceutical's stock experienced volatility, initially rising by 10.08% on December 10 before closing at a limit down of 3.74 yuan per share the next day [4][14] - As of December 15, the stock price further declined to 3.3 yuan per share, reflecting the negative impact of the bribery allegations on market perception [19] Group 3: Business Performance Challenges - Despite implementing cost control measures, Xinbang Pharmaceutical's financial performance has continued to decline, with a reported revenue of 60.32 billion yuan in 2024, down 6.63% year-on-year, and a net profit of 1.01 billion yuan, a 64.7% decrease from 2023 [9][19] - In the first half of 2025, revenue fell by 6.62% to 28.45 billion yuan, with significant declines in its core businesses, particularly a 12.1% drop in pharmaceutical distribution [20] - The company has managed to reduce operating costs, with a 5.92% decrease in total operating costs in the first half of 2025, yet net profit still fell by 6.69% to 1.07 billion yuan [10][21] Group 4: Governance Concerns - Xinbang Pharmaceutical's family-style management has raised concerns about its governance capabilities, with significant ownership held by An Huailuo and his daughter An Ji [19] - The company has faced legal disputes regarding board representation, which have further complicated its governance structure [19] - Recent personal controversies involving An Ji have also drawn public attention, adding to the scrutiny of the company's management practices [19]